Latest news with #NorthBrunswick
CBS News
25-06-2025
- Politics
- CBS News
N.J. Judge Esther Salas speaks after Minnesota lawmaker shootings, which bear similarity to her son's killing
Slain Minnesota lawmaker Melissa Hortman and her husband, Mark, who were gunned down at their home on June 14, will be laid to rest this weekend. Authorities say the gunman was politically motivated. The tragedy is eerily similar to what unfolded at the home of federal Judge Esther Salas almost five years ago when her son was murdered. Judge's son fatally shot at New Jersey home "I sit here on what will be five years without the most important person in my life, and it makes me sad that we're, we're still struggling with so much hatred," she told CBS News New York's Lisa Rozner. Salas says she's sad to see public officials gunned down since her own tragedy on July 19, 2020. Salas and her husband Mark Anderl were celebrating their son Daniel's 20th birthday at their North Brunswick home when a man dressed as a delivery worker rang the bell. He fatally shot Daniel. Her husband was also wounded, but survived. "When I was told by the doctors that my son didn't make it, I didn't want to live," Salas said. But through faith, friendship and family, she survived - and is speaking out. Daniel's Law in New Jersey protects public officials' personal information from being disclosed online, and in 2022, a federal law in her son's name was created prohibiting the posting of data, like addresses and phone numbers, of federal judges and their family. "I know their pain, and I'm sending them love" Nationwide, threats of political violence are on the rise. Since 2017, Capitol Police say threats against members of Congress are up 140%, the highest they've ever been. A 2023 national survey from the Brennan Center for Justice found 43% of state legislators experience threats. Salas says it hit close to home when she learned of the assassinations of Hortman and her husband. Like Salas' case, the suspect impersonated someone – in this case, law enforcement – and rang the doorbell before shooting. She has some advice for Hortman's family, as someone who has unfortunately been in their shoes. "They need to huddle together, to let people help them," she said. "I know their pain, and I'm sending them love ... I think it's necessary." Salas has been organizing online forums called "Speak Up For Justice" so people across the country can voice their support for the judiciary in a nonpartisan way. One of those forums is being held at 9 a.m. Thursday.
Associated Press
10-06-2025
- Health
- Associated Press
BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS)
NORTH BRUNSWICK, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for acute and chronic inflammatory diseases, announces that it will conduct a Phase 2 study of rhu-pGSN for decompression sickness (DCS) under a contract awarded by the U.S. Navy's Office of Naval Research to the University of Maryland School of Medicine (UMSOM). This work is the culmination of an extended collaboration with Dr. Stephen Thom, Professor of Emergency Medicine at UMSOM. The Company's portfolio is built around gelsolin, a highly conserved and critical immune regulatory protein which rebalances dysfunctional inflammation without suppressing immune function. Phase 2 Clinical Trial of Rhu-pGSN The study, 'Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers,' NCT06216366 is being conducted under a contract with the Office of Naval Research with the University of Maryland. It will investigate the use of rhu-pGSN as a pre- or post-exposure intervention in healthy trained SCUBA divers exposed to controlled hyperbaric conditions. The study is designed to assess the impact of rhu-pGSN on key inflammatory responses and microparticle production associated with decompression. Decompression sickness occurs when inert gas bubbles form in the bloodstream and tissues due to rapid pressure changes, triggering an inflammatory cascade. Previous studies have shown that individuals with DCS exhibit depleted levels of plasma gelsolin and elevated levels of microparticles that contain inflammatory cytokines. In animal models, supplementation with rhu-pGSN both prevented and mitigated DCS-related complications. This randomized, double-blind, placebo-controlled study will enroll healthy trained SCUBA divers at a single site and expose them to a standardized hyperbaric protocol (30 meters of seawater for 35 minutes). Participants will be randomized into three groups to receive either pre-exposure or post-exposure rhu-pGSN, or placebo. The study will assess a broad range of outcomes including plasma gelsolin levels, inflammatory markers like IL-1β, gas bubble formation, and well-being metrics. Dr. Thom states, 'If successful, this study could transform the way we manage decompression sickness by providing a portable, field-deployable treatment option. Reducing our reliance on hyperbaric chambers would greatly expand our ability to treat DCS in remote or operational environments, improving outcomes and readiness, a key goal for the Navy.' BioAegis and University of Maryland are co-applicants on a patent filing listing Dr. Thom as an inventor. Gelsolin: A Multitasking Protein for Complex Inflammatory Conditions Rhu-pGSN holds immense promise as a therapeutic intervention for serious acute and chronic conditions due to its multifaceted mechanism of action. In critical illness, gelsolin levels collapse, causing adverse outcomes. Supplementing gelsolin addresses this deficit directly, restoring immune balance while preserving host defense and rhu-pGSN has been shown in animal studies to: Supplementation with the recombinant gelsolin protein holds promise to address the overzealous inflammatory response associated many inflammatory diseases without suppressing immune function. About BioAegis BioAegis Therapeutics Inc. is a NJ-based clinical-stage private company whose mission is to capitalize on a key regulatory component of the body's immune system, plasma gelsolin, to prevent adverse outcomes in diseases driven by inflammation. BioAegis has the exclusive license to broad, worldwide intellectual property through Harvard-Brigham and Women's Hospital. It holds over 40 patents issued for coverage of inflammatory disease, infection, renal failure, neurologic disease, and frailty. BioAegis will also have U.S. biologics exclusivity and has recently filed new IP in areas of unmet need. BioAegis' lead product, rhu-pGSN, is currently being studied in a 600-patient global Phase 2 trial for patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS). This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50123C00067. NCT05947955 Investor Inquiries: Steven Cordovano 203-952-6373 [email protected] Media Inquiries: Christine Lagana [email protected]
